
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)*

Allogene Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

1

David D. Chang, M.D., Ph.D.

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

UNITED STATES

Number of Shares	5	Sole Voting Power
Beneficially Owned by Each Reporting Person	9,384,158.00	Shared Voting Power
With:	6	
	2,913,196.00	Sole Dispositive Power
	7	
	9,384,158.00	Shared Dispositive Power
	8	
	2,913,196.00	
Aggregate Amount Beneficially Owned by Each Reporting Person	9	
	12,297,354.00	
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)	10	
	<input type="checkbox"/>	
Percent of class represented by amount in row (9)	11	
	4.9 %	
Type of Reporting Person (See Instructions)	12	
	IN	

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons	1
Chang 2006 Family Trust	
Check the appropriate box if a member of a Group (see instructions)	2
<input type="checkbox"/> (a)	
<input type="checkbox"/> (b)	
Sec Use Only	3
Citizenship or Place of Organization	4
CALIFORNIA	
Sole Voting Power	5
	0.00
Number of Shares Beneficially Owned by Each Reporting Person	6
With:	1,201,108.00
	7
	Sole Dispositive Power
	0.00
	8
	Shared Dispositive Power
	1,201,108.00
Aggregate Amount Beneficially Owned by Each Reporting Person	9
	1,201,108.00
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)	10
	<input type="checkbox"/>

11 Percent of class represented by amount in row (9)

0.5 %

Type of Reporting Person (See Instructions)

12

OO

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

1

JEC 2019 Trust

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

CALIFORNIA

Sole Voting Power

5

0.00

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:

Shared Voting Power

6

856,044.00

Sole Dispositive Power

7

0.00

Shared Dispositive

8

Power

856,044.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

856,044.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

0.3 %

Type of Reporting Person (See Instructions)

12

OO

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

1

RTC 2019 Trust

2

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

3 Sec Use Only
Citizenship or Place of Organization

4 CALIFORNIA

Sole Voting Power

5

856,044.00

Number of Shares Beneficially Owned by Each Reporting Person With:

Shared Voting Power

6

0.00

Sole Dispositive Power

7

856,044.00

Shared Dispositive

8

Power

0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

856,044.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

0.3 %

Type of Reporting Person (See Instructions)

12

OO

SCHEDULE 13G

Item 1.

Name of issuer:

(a)

Allogene Therapeutics, Inc.

Address of issuer's principal executive offices:

(b)

210 East Grand Avenue, South San Francisco, CA, 94080.

Item 2.

Name of person filing:

(a)

David D. Chang, M.D., Ph.D. Chang 2006 Family Trust JEC 2019 Trust RTC 2019 Trust

Address or principal business office or, if none, residence:

(b)

David D. Chang, M.D., Ph.D.: 1755 Ocean Avenue, #803, Santa Monica, CA 90401 Chang 2006 Family Trust: 1755 Ocean Avenue, #803, Santa Monica, CA 90401 JEC 2019 Trust: 1755 Ocean Avenue, #803, Santa Monica, CA 90401 RTC 2019 Trust: 1755 Ocean Avenue, #803, Santa Monica, CA 90401

Citizenship:

(c)

David D. Chang, M.D. Ph.D.: USA Chang 2006 Family Trust: California JEC 2019 Trust: California RTC 2019 Trust: California

Title of class of securities:

(d)

Common Stock

(e)

CUSIP No.:

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
- (k) Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

Amount beneficially owned:

- (a) Row 9 of each Reporting Person's cover page to this Schedule 13G/A sets forth the aggregate number of shares of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. Row 9 of Dr. Chang's cover page includes 6,345,007 shares of common stock issuable within 60 days of March 31, 2026 upon the exercise of stock options held by Dr. Chang, and also includes (a) 1,201,108 shares of common stock beneficially owned by the Chang 2006 Family Trust, of which Dr. Chang is co-trustee, (b) 856,044 shares of common stock beneficially owned by the JEC 2019 Trust, of which Dr. Chang is co-trustee and (c) 856,044 shares of common stock beneficially owned by the RTC 2019 Trust, of which Dr. Chang is co-trustee.

Percent of class:

- (b) Row 11 of each Reporting Person's cover page to this Schedule 13G/A sets forth the percentages of the shares of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. This percentage is calculated based on 243,777,920 shares of common stock outstanding as of March 10, 2026, as reported in the Issuer's Quarterly Report on Form 10-K filed on March 12, 2026. %

- (c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

Row 5 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.

(ii) Shared power to vote or to direct the vote:

Row 6 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.

(iii) Sole power to dispose or to direct the disposition of:

Row 7 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to dispose or to direct the disposition of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.

(iv) Shared power to dispose or to direct the disposition of:

Row 8 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to dispose or to direct the disposition of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.

Item 5. Ownership of 5 Percent or Less of a Class.

Ownership of 5 percent or less of a class

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

David D. Chang, M.D., Ph.D.

Signature: /s/ David D. Chang

Name/Title: David D. Chang, M.D., Ph.D.

Date: 05/13/2026

Chang 2006 Family Trust

Signature: /s/ David D. Chang

Name/Title: By David D. Chang, M.D., Ph.D., Co-Trustee

Date: 05/13/2026

JEC 2019 Trust

Signature: /s/ David D. Chang

Name/Title: By David D. Chang, M.D., Ph.D., Co-Trustee

Date: 05/13/2026

RTC 2019 Trust

Signature: /s/ David D. Chang

Name/Title: By David D. Chang, M.D., Ph.D., Co-Trustee

Date: 05/13/2026

Exhibit Information

Joint Filing Agreement

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the common stock of Allogene Therapeutics, Inc., a Delaware corporation, and that this Agreement may be included as an Exhibit to such joint filing. This Agreement may be executed in any number of counterparts all of which, taken together, shall constitute one and the same instrument.

Dated: May 13, 2026

/s/ David D. Chang

David D. Chang, M.D., Ph.D.

Chang 2006 Family Trust

By: /s/ David D. Chang

Name: David D. Chang, M.D., Ph.D., Co-Trustee

JEC 2019 Trust

By: /s/ David D. Chang

Name: David D. Chang, M.D., Ph.D., Co-Trustee

RTC 2019 Trust

By: /s/ David D. Chang

Name: David D. Chang, M.D., Ph.D., Co-Trustee